BostonGene to Present Multiple Abstracts at the 2019 American Society of Hematology (ASH) Annual Meeting

WALTHAM, MA, November 21, 2019 — BostonGene Corporation (BostonGene), a Boston-based biomedical software company, today announced that as a result of its collaborations, multiple abstracts have been accepted for presentation at the 61st American Society of Hematology Annual Meeting and Exposition to be held December 7-10, 2019 in Orlando, Florida. In addition, BostonGene will exhibit at booth #152 in Hall B.

The presentations will provide results demonstrating the role of the tumor microenvironment in cancer classification and treatment outcomes. By combing whole exome and transcriptome sequencing analysis, the significance of stromal and immune compartments of microenvironment in therapeutically relevant categories of Mantle Cell Lymphomas and Diffuse Large B-Cell Lymphoma (DLBCL) is identified.

POSTER PRESENTATION

Sunday, December 8, 2019: 6:00 PM - 8:00 PM in Hall B, Level 2

• Title: Tumor Microenvironment Molecular Signatures That Define Therapeutic Resistance in Mantle Cell Lymphoma (Abstract 2762)


• Presenter: Krystle Nomie, The University of Texas MD Anderson Cancer Center


• Session: Lymphoma—Genetic/Epigenetic Biology: Poster II

ORAL PRESENTATION

Monday, December 9, 2019: 10:45 AM in Tangerine 2 (WF2), Level 2

• Title: Microenvironmental Signatures Reveal Biological Subtypes of Diffuse Large B-Cell Lymphoma (DLBCL) Distinct from Tumor Cell Molecular Profiling (Abstract 656)


• Presenter: Leandro Cerchietti, MD, Weill Cornell Medicine


• Session: Lymphoma Biology—Non-Genetic Studies: Tumor Microenvironment

Additional information on abstracts for ASH Annual Meeting can found here: http://www.hematology.org/Annual-Meeting/.

“We are excited to share our success as a strategic collaborator with two of the leading cancer centers in the world at this year’s ASH event. We look forward to showcasing our innovative platform that will ultimately impact and improve cancer patients’ chances for survival,” said Andrew Feinberg, President & CEO at BostonGene.

About BostonGene Corporation

BostonGene powers an AI model of tumor and immune biology to deliver disease-level insights and enable precision decision-making across oncology and immune-mediated diseases, spanning drug development and clinical care. By integrating multimodal data, including genomic, transcriptomic, immune, and clinical signals, BostonGene generates biologically grounded intelligence to optimize patient selection, trial design, and therapeutic strategy. This creates a scalable AI decision layer that improves development outcomes and clinical management. BostonGene partners with leading biopharmaceutical organizations and academic institutions to accelerate the delivery of precision therapies while continuously expanding its capabilities across new diseases and complex biological systems. For more information, visit www.BostonGene.com.